Genentech reports five-year data from trial of Susvimo for wet AMD
The IVT-Susvimo cohort showed a BCVA of 68.6 letters at a five-year period from a 76.3 baseline.
04 August 2025
04 August 2025
The IVT-Susvimo cohort showed a BCVA of 68.6 letters at a five-year period from a 76.3 baseline.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.